BCR-ABL and JAK2V617F Mutation Co-existence, Rare or Just Unexplored

Area of Science:

• Hematology
• Molecular Genetics
• Oncology

Background:

• Chronic myeloid leukemia (CML) and myeloproliferative neoplasms (MPNs) are distinct hematologic disorders.
• CML is typically associated with the BCR-ABL fusion gene, while MPNs often feature the JAK2V617F mutation.
• Coexistence of both mutations in a single patient is rare but reported.

Purpose of the Study:

• To report two cases of concurrent BCR-ABL and JAK2V617F mutations.
• To discuss the clinical presentation and diagnostic challenges of such coexistent mutations.
• To review the current management strategies for patients with both mutations.

Main Methods:

• Case report of two patients with coexisting BCR-ABL and JAK2V617F mutations.
• Clinical data collection including hematological parameters and mutation status.
• Review of existing literature on dual mutations in CML and MPNs.

Main Results:

• Two patients were identified with both BCR-ABL and JAK2V617F mutations.
• Case 1: Initially treated for CML, persistent thrombocytosis led to JAK2V617F detection.
• Case 2: Presented with CML-like symptoms and high platelets, positive for both mutations upfront.
• These are the first reported cases from India with coexistent BCR-ABL and JAK2V617F mutations.

Conclusions:

• The co-occurrence of BCR-ABL and JAK2V617F mutations presents diagnostic and therapeutic challenges.
• Careful clinical and molecular evaluation is crucial for accurate diagnosis in such cases.
• Further research is needed to establish optimal management guidelines for patients with dual mutations.